Madison Honey, PhD candidate, Amsterdam University Medical Centre, Amsterdam, Netherlands, presents the findings of a study assessing the diagnostic performance of glial fibrillary acidic protein (GFAP) to distinguish between controls, Alzheimer’s disease (AD), and dementia with Lewy bodies (DLB). More than 370 cognitively normal individuals, 250 patients with AD, and 120 patients with DLB were included in the study and GFAP levels were measured in one, two, or three of cerebrospinal fluid (CSF), serum, and plasma. GFAP levels were increased in all biofluids in patients with AD, compared to controls and patients with DLB. No difference in levels were seen between DLB and control cohorts. When assessing the impact of age, it was shown that differences in GFAP levels between controls and patients with AD become harder to detect with age. CSF GFAP levels increased with age in the AD group, but plasma and serum levels did not. GFAP levels in cognitively normal individuals increased with age across all biofluids. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
